Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV
Biotech
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
The partners guided their once-weekly therapy past another milestone, linking the cocktail to sustained suppression of the virus out to 48 weeks.
Nick Paul Taylor
Oct 21, 2024 5:06am
A seventh known patient seems cured of HIV
Jul 18, 2024 1:59pm
GSK sets diversity targets, partners with DEI firm for education
May 22, 2024 11:00am
Merck-Gilead's weekly HIV combo maintains viral suppression
Mar 6, 2024 11:08am
CytoDyn finally clears FDA hold on HIV program after 2 years
Feb 29, 2024 10:20am
HIV protein inhibited by Rukobia linked to cardio comorbidities
Nov 30, 2023 9:30am
